See more : SML Isuzu Limited (SMLISUZU.BO) Income Statement Analysis – Financial Results
Complete financial analysis of REGENXBIO Inc. (RGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of REGENXBIO Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Investeringsforeningen Jutlanderinvest – Varkst (SDIVKS.CO) Income Statement Analysis – Financial Results
- Zhejiang Dongri Limited Company (600113.SS) Income Statement Analysis – Financial Results
- Sustainable Development Acquisition I Corp. (SDACW) Income Statement Analysis – Financial Results
- Quanergy Systems, Inc. (QNGY) Income Statement Analysis – Financial Results
- Tuesday Morning Corporation (TUEMQ) Income Statement Analysis – Financial Results
REGENXBIO Inc. (RGNX)
About REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.24M | 112.72M | 470.35M | 154.57M | 35.23M | 218.51M | 10.39M | 4.59M | 7.59M | 6.12M | 6.09M |
| Cost of Revenue | 37.21M | 54.55M | 51.83M | 35.71M | 8.24M | 9.64M | 1.71M | 959.00K | 1.50M | 1.01M | 324.00K |
| Gross Profit | 53.03M | 58.18M | 418.51M | 118.85M | 26.99M | 208.87M | 8.68M | 3.63M | 6.09M | 5.11M | 5.76M |
| Gross Profit Ratio | 58.76% | 51.61% | 88.98% | 76.89% | 76.61% | 95.59% | 83.56% | 79.10% | 80.19% | 83.55% | 94.68% |
| Research & Development | 232.27M | 242.45M | 181.44M | 166.29M | 124.19M | 83.87M | 57.22M | 45.48M | 17.28M | 4.96M | 5.05M |
| General & Administrative | 88.49M | 85.28M | 79.33M | 63.82M | 51.82M | 36.85M | 27.23M | 23.59M | 11.91M | 3.85M | 5.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 88.49M | 85.28M | 79.33M | 63.82M | 51.82M | 36.85M | 27.23M | 23.59M | 11.91M | 3.85M | 5.47M |
| Other Expenses | 397.00K | -6.68M | -2.24M | 7.98M | -10.00K | 42.00K | 116.00K | -102.00K | -26.00K | -47.00K | 0.00 |
| Operating Expenses | 321.16M | 321.06M | 258.53M | 238.09M | 175.99M | 120.77M | 84.57M | 68.97M | 29.17M | 8.77M | 10.53M |
| Cost & Expenses | 358.37M | 375.60M | 310.37M | 273.80M | 184.23M | 130.41M | 86.28M | 69.93M | 30.67M | 9.77M | 10.85M |
| Interest Income | 25.00K | 342.00K | 719.00K | 4.27M | 2.95M | 8.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.86M | 23.25M | 26.28M | 771.00K | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 321.00K | 611.00K |
| Depreciation & Amortization | 17.32M | 12.91M | 9.56M | 8.41M | 7.15M | 3.98M | 2.69M | 544.00K | 80.00K | 30.00K | 14.00K |
| EBITDA | -239.46M | -244.24M | 169.54M | -96.83M | -90.34M | 92.08M | -73.20M | -64.80M | -22.71M | -3.65M | -4.78M |
| EBITDA Ratio | -265.36% | -232.90% | 34.17% | -74.38% | -560.72% | 37.08% | -756.29% | -1,423.84% | -304.16% | -59.67% | -78.23% |
| Operating Income | -268.13M | -262.88M | 159.98M | -119.23M | -149.00M | 88.10M | -75.89M | -65.34M | -23.14M | -3.68M | -4.78M |
| Operating Income Ratio | -297.12% | -233.20% | 34.01% | -77.14% | -422.89% | 40.32% | -730.15% | -1,423.84% | -304.92% | -60.16% | -78.46% |
| Total Other Income/Expenses | 4.48M | -17.53M | -18.73M | 13.22M | 51.51M | 16.02M | 2.72M | 1.94M | 326.00K | -321.00K | -611.00K |
| Income Before Tax | -263.65M | -280.41M | 141.25M | -106.01M | -97.49M | 104.12M | -73.17M | -63.40M | -22.81M | -4.00M | -5.39M |
| Income Before Tax Ratio | -292.15% | -248.75% | 30.03% | -68.59% | -276.70% | 47.65% | -704.02% | -1,381.61% | -300.62% | -65.41% | -88.50% |
| Income Tax Expense | -152.00K | -84.00K | 13.41M | 5.24M | -2.76M | 4.18M | 686.00K | -435.00K | -60.00K | 291.00K | 597.00K |
| Net Income | -263.49M | -280.32M | 127.84M | -111.25M | -94.73M | 99.94M | -73.17M | -62.97M | -22.81M | -4.00M | -5.39M |
| Net Income Ratio | -291.99% | -248.68% | 27.18% | -71.98% | -268.88% | 45.74% | -704.02% | -1,372.13% | -300.62% | -65.41% | -88.50% |
| EPS | -6.02 | -6.50 | 3.01 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 | -0.41 |
| EPS Diluted | -6.02 | -6.50 | 2.91 | -2.98 | -2.58 | 2.73 | -2.45 | -2.38 | -2.49 | -0.30 | -0.41 |
| Weighted Avg Shares Out | 43.73M | 43.15M | 42.44M | 37.28M | 36.69M | 36.61M | 29.86M | 26.41M | 9.17M | 13.15M | 13.15M |
| Weighted Avg Shares Out (Dil) | 43.73M | 43.15M | 43.91M | 37.28M | 36.69M | 36.65M | 29.88M | 26.41M | 9.17M | 13.15M | 13.15M |
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
REGENXBIO Reports Second Quarter 2023 Financial Results and Recent Operational Highlights
REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
Regenxbio could be a gene therapy pioneer with multiple ways to win in 2023
REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference
REGENXBIO to Participate in Upcoming Investor Conferences
Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?
Source: https://incomestatements.info
Category: Stock Reports